Traws Pharma, Inc. Common Stock
TRAWTraws Pharma, Inc. (TRAW) is a biotechnology company focusing on the development of innovative pharmaceutical products. The company is dedicated to researching and bringing to market therapies aimed at addressing unmet medical needs, with a particular emphasis on novel formulations and delivery systems. Traws Pharma aims to leverage cutting-edge science to improve patient outcomes across various therapeutic areas.
Company News
Traws Pharma announced the deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA. While the compound showed potent efficacy in animal models, the company is advancing backup candidates with similar pharmacokinetic profiles while maintaining cash runway through...
Traws Pharma initiated Phase 2 clinical trials for ratutrelvir, a ritonavir-free COVID-19 treatment, comparing its safety and efficacy against PAXLOVID®. The company expects to report trial results by year-end 2025, targeting potential improvements in COVID treatment.
Traws Pharma, a clinical-stage biopharmaceutical company, is developing novel antiviral therapies targeting respiratory viral diseases like bird flu, seasonal influenza, and COVID-19. The company submitted a Phase 2 protocol for tivoxavir marboxil and briefing documents to the FDA for a Type D meeting.
Traws Pharma announces the publication of positive clinical data for its legacy oncology drug rigosertib in treating recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB SCC), a rare and aggressive form of skin cancer.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
